Other important TKIs include ALK inhibitors such as alectinib, brigatinib, ceritinib, crizotinib, entrectinib, and lorlatinib, which are mainly used in ALK-positive NSCLC [92]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.